Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression

Nour Majbour, Nishant Vaikath, Paolo Eusebi, Davide Chiasserini, Mustafa Ardah, Shiji Varghese, M. Emdadul Haque, Takahiko Tokuda, Peggy Auinger, Paolo Calabresi, Lucilla Parnetti, Omar Ali El-Agnaf

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background: Parkinson's disease (PD) diagnosis is mainly based on clinical criteria, with a high risk of misdiagnosis. The identification of reliable biomarkers for disease diagnosis and progression has a key role for developing disease-modifying therapies. In this article, we investigated the longitudinal changes of CSF α-synuclein species in early PD patients and explored the potential use of these species as surrogate biomarkers for PD progression. Methods: We used our newly developed enzyme-linked immunosorbent assay systems for measuring different forms of α-synuclein, such as oligomeric-α-synuclein, phosphorylated-α-synuclein at serine 129, or total-α-synuclein in CSF from the longitudinal Deprenyl and Tocopherol Antioxidative Therapy for Parkinsonism study cohort (n = 121). CSF Alzheimer's disease biomarkers (total-tau, phosphorylated-tau, Aβ40, and Aβ42) were also measured for this cohort. Results: Interestingly, total-α-synuclein and oligomeric-α-synuclein levels significantly increased during the 2-year Deprenyl and Tocopherol Antioxidative Therapy for Parkinsonism study follow-up period, whereas phosphorylated-α-synuclein at serine 129 levels showed a longitudinal decrease. We have also noted an association between a change of the oligomeric-α-synuclein/total-α-synuclein ratio and a worsening of motor signs, in particular in the postural-instability and gait-difficulty dominant PD group. A strong positive correlation between the changes in CSF total-α-synuclein and oligomeric-α-synuclein during the 2-year Deprenyl and Tocopherol Antioxidative Therapy for Parkinsonism study was also noted (r = 0.84, P <.001). Conclusion: Our data show that CSF α-synuclein species have a dynamic pattern along the course of the disease, supporting their possible role as progression biomarkers for PD and their link with PD clinical phenotypes.

Original languageEnglish
Pages (from-to)1535-1542
Number of pages8
JournalMovement Disorders
Volume31
Issue number10
DOIs
Publication statusPublished - 1 Oct 2016

Fingerprint

Synucleins
alpha-Synuclein
Parkinson Disease
Disease Progression
Selegiline
Tocopherols
Parkinsonian Disorders
Biomarkers
Serine
Therapeutics
Diagnostic Errors

Keywords

  • alpha-synuclein
  • biomarkers
  • DATATOP
  • oligomers
  • Parkinson's disease

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression. / Majbour, Nour; Vaikath, Nishant; Eusebi, Paolo; Chiasserini, Davide; Ardah, Mustafa; Varghese, Shiji; Haque, M. Emdadul; Tokuda, Takahiko; Auinger, Peggy; Calabresi, Paolo; Parnetti, Lucilla; Ali El-Agnaf, Omar.

In: Movement Disorders, Vol. 31, No. 10, 01.10.2016, p. 1535-1542.

Research output: Contribution to journalArticle

Majbour, N, Vaikath, N, Eusebi, P, Chiasserini, D, Ardah, M, Varghese, S, Haque, ME, Tokuda, T, Auinger, P, Calabresi, P, Parnetti, L & Ali El-Agnaf, O 2016, 'Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression', Movement Disorders, vol. 31, no. 10, pp. 1535-1542. https://doi.org/10.1002/mds.26754
Majbour, Nour ; Vaikath, Nishant ; Eusebi, Paolo ; Chiasserini, Davide ; Ardah, Mustafa ; Varghese, Shiji ; Haque, M. Emdadul ; Tokuda, Takahiko ; Auinger, Peggy ; Calabresi, Paolo ; Parnetti, Lucilla ; Ali El-Agnaf, Omar. / Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression. In: Movement Disorders. 2016 ; Vol. 31, No. 10. pp. 1535-1542.
@article{15da3e6237a44165abbc6ceb001f3dea,
title = "Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression",
abstract = "Background: Parkinson's disease (PD) diagnosis is mainly based on clinical criteria, with a high risk of misdiagnosis. The identification of reliable biomarkers for disease diagnosis and progression has a key role for developing disease-modifying therapies. In this article, we investigated the longitudinal changes of CSF α-synuclein species in early PD patients and explored the potential use of these species as surrogate biomarkers for PD progression. Methods: We used our newly developed enzyme-linked immunosorbent assay systems for measuring different forms of α-synuclein, such as oligomeric-α-synuclein, phosphorylated-α-synuclein at serine 129, or total-α-synuclein in CSF from the longitudinal Deprenyl and Tocopherol Antioxidative Therapy for Parkinsonism study cohort (n = 121). CSF Alzheimer's disease biomarkers (total-tau, phosphorylated-tau, Aβ40, and Aβ42) were also measured for this cohort. Results: Interestingly, total-α-synuclein and oligomeric-α-synuclein levels significantly increased during the 2-year Deprenyl and Tocopherol Antioxidative Therapy for Parkinsonism study follow-up period, whereas phosphorylated-α-synuclein at serine 129 levels showed a longitudinal decrease. We have also noted an association between a change of the oligomeric-α-synuclein/total-α-synuclein ratio and a worsening of motor signs, in particular in the postural-instability and gait-difficulty dominant PD group. A strong positive correlation between the changes in CSF total-α-synuclein and oligomeric-α-synuclein during the 2-year Deprenyl and Tocopherol Antioxidative Therapy for Parkinsonism study was also noted (r = 0.84, P <.001). Conclusion: Our data show that CSF α-synuclein species have a dynamic pattern along the course of the disease, supporting their possible role as progression biomarkers for PD and their link with PD clinical phenotypes.",
keywords = "alpha-synuclein, biomarkers, DATATOP, oligomers, Parkinson's disease",
author = "Nour Majbour and Nishant Vaikath and Paolo Eusebi and Davide Chiasserini and Mustafa Ardah and Shiji Varghese and Haque, {M. Emdadul} and Takahiko Tokuda and Peggy Auinger and Paolo Calabresi and Lucilla Parnetti and {Ali El-Agnaf}, Omar",
year = "2016",
month = "10",
day = "1",
doi = "10.1002/mds.26754",
language = "English",
volume = "31",
pages = "1535--1542",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression

AU - Majbour, Nour

AU - Vaikath, Nishant

AU - Eusebi, Paolo

AU - Chiasserini, Davide

AU - Ardah, Mustafa

AU - Varghese, Shiji

AU - Haque, M. Emdadul

AU - Tokuda, Takahiko

AU - Auinger, Peggy

AU - Calabresi, Paolo

AU - Parnetti, Lucilla

AU - Ali El-Agnaf, Omar

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Background: Parkinson's disease (PD) diagnosis is mainly based on clinical criteria, with a high risk of misdiagnosis. The identification of reliable biomarkers for disease diagnosis and progression has a key role for developing disease-modifying therapies. In this article, we investigated the longitudinal changes of CSF α-synuclein species in early PD patients and explored the potential use of these species as surrogate biomarkers for PD progression. Methods: We used our newly developed enzyme-linked immunosorbent assay systems for measuring different forms of α-synuclein, such as oligomeric-α-synuclein, phosphorylated-α-synuclein at serine 129, or total-α-synuclein in CSF from the longitudinal Deprenyl and Tocopherol Antioxidative Therapy for Parkinsonism study cohort (n = 121). CSF Alzheimer's disease biomarkers (total-tau, phosphorylated-tau, Aβ40, and Aβ42) were also measured for this cohort. Results: Interestingly, total-α-synuclein and oligomeric-α-synuclein levels significantly increased during the 2-year Deprenyl and Tocopherol Antioxidative Therapy for Parkinsonism study follow-up period, whereas phosphorylated-α-synuclein at serine 129 levels showed a longitudinal decrease. We have also noted an association between a change of the oligomeric-α-synuclein/total-α-synuclein ratio and a worsening of motor signs, in particular in the postural-instability and gait-difficulty dominant PD group. A strong positive correlation between the changes in CSF total-α-synuclein and oligomeric-α-synuclein during the 2-year Deprenyl and Tocopherol Antioxidative Therapy for Parkinsonism study was also noted (r = 0.84, P <.001). Conclusion: Our data show that CSF α-synuclein species have a dynamic pattern along the course of the disease, supporting their possible role as progression biomarkers for PD and their link with PD clinical phenotypes.

AB - Background: Parkinson's disease (PD) diagnosis is mainly based on clinical criteria, with a high risk of misdiagnosis. The identification of reliable biomarkers for disease diagnosis and progression has a key role for developing disease-modifying therapies. In this article, we investigated the longitudinal changes of CSF α-synuclein species in early PD patients and explored the potential use of these species as surrogate biomarkers for PD progression. Methods: We used our newly developed enzyme-linked immunosorbent assay systems for measuring different forms of α-synuclein, such as oligomeric-α-synuclein, phosphorylated-α-synuclein at serine 129, or total-α-synuclein in CSF from the longitudinal Deprenyl and Tocopherol Antioxidative Therapy for Parkinsonism study cohort (n = 121). CSF Alzheimer's disease biomarkers (total-tau, phosphorylated-tau, Aβ40, and Aβ42) were also measured for this cohort. Results: Interestingly, total-α-synuclein and oligomeric-α-synuclein levels significantly increased during the 2-year Deprenyl and Tocopherol Antioxidative Therapy for Parkinsonism study follow-up period, whereas phosphorylated-α-synuclein at serine 129 levels showed a longitudinal decrease. We have also noted an association between a change of the oligomeric-α-synuclein/total-α-synuclein ratio and a worsening of motor signs, in particular in the postural-instability and gait-difficulty dominant PD group. A strong positive correlation between the changes in CSF total-α-synuclein and oligomeric-α-synuclein during the 2-year Deprenyl and Tocopherol Antioxidative Therapy for Parkinsonism study was also noted (r = 0.84, P <.001). Conclusion: Our data show that CSF α-synuclein species have a dynamic pattern along the course of the disease, supporting their possible role as progression biomarkers for PD and their link with PD clinical phenotypes.

KW - alpha-synuclein

KW - biomarkers

KW - DATATOP

KW - oligomers

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=84991246672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991246672&partnerID=8YFLogxK

U2 - 10.1002/mds.26754

DO - 10.1002/mds.26754

M3 - Article

VL - 31

SP - 1535

EP - 1542

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 10

ER -